Approves Leqembi Iqlik (Lecanemab-Irmb) Subcutaneous Injection For Maintenance Dosing For Treatment Of Early Alzheimer's Disease
01/09/2025 24:31
Sept 1 (Reuters) - Eisai Co Ltd 4523.T: EISAI CO LTD - APPROVES LEQEMBI IQLIK (LECANEMAB-IRMB) SUBCUTANEOUS INJECTION FOR MAINTENANCE DOSING FOR TREATMENT OF EARLY ALZHEIMER'S DISEASE Source text: ID:nTSte86588 Further company coverage: 4523.T
Recent news on Eisai
See all newsBiogen tops quarterly estimates on rare-disease drug strength (updated)
Biogen beats third-quarter results on strength in rare disease drugs
Brief: FDA Approves Belzutifan-Lenvatinib Combination for Advanced Renal Cell Carcinoma With A Clear Cell Component
Leqembi Pen (Subcutaneous Formulation Of Leqembi) Approved In Japan
Leqembi (Lecanemab) Subcutaneous Formulation As An Initiation Treatment For Early Alzheimer's Disease Approved In China